International Assets Investment Management LLC Sells 5,601 Shares of Medtronic PLC $MDT

International Assets Investment Management LLC lessened its stake in Medtronic PLC (NYSE:MDT) by 36.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,690 shares of the medical technology company’s stock after selling 5,601 shares during the quarter. International Assets Investment Management LLC’s holdings in Medtronic were worth $825,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Activest Wealth Management increased its stake in Medtronic by 470.9% during the third quarter. Activest Wealth Management now owns 314 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 259 shares during the last quarter. IAG Wealth Partners LLC purchased a new stake in shares of Medtronic during the 2nd quarter worth about $30,000. Pin Oak Investment Advisors Inc. purchased a new stake in shares of Medtronic during the 2nd quarter worth about $32,000. Global Assets Advisory LLC purchased a new stake in shares of Medtronic during the 1st quarter worth about $36,000. Finally, Core Capital Management & Research inc. acquired a new stake in Medtronic during the 2nd quarter worth approximately $33,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on MDT. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $92.00 price target on shares of Medtronic in a research report on Thursday, September 3rd. Stifel Nicolaus raised their target price on shares of Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a research note on Wednesday, September 2nd. Weiss Ratings upgraded shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 19th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $118.00 price target on shares of Medtronic in a research report on Wednesday, September 2nd. Finally, Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a report on Saturday, October 31st. Eighteen analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.88.

Medtronic Trading Up 6.2%

NYSE MDT opened at $105.02 on Thursday. The stock has a market cap of $134.34 billion, a P/E ratio of 17.29, a PEG ratio of 2.31 and a beta of 0.56. The company’s fifty day simple moving average is $92.21 and its 200-day simple moving average is $88.39. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same period last year, the business earned $1.26 EPS. The business’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts predict that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were paid a dividend of $0.72 per share. The ex-dividend date was Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 2.7%. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Insider Activity

In other Medtronic news, EVP Michael Marinaro sold 10,420 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the sale, the executive vice president owned 105,916 shares in the company, valued at $10,167,936. This trade represents a 8.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president owned 42,186 shares in the company, valued at $3,950,718.90. This represents a 3.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,903 shares of company stock worth $5,889,203 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported that the SPYRAL AFFIRM real-world study found statistically significant, clinically meaningful blood-pressure reductions six months after treatment with its Symplicity Spyral system. Reductions were seen in office, home, and 24-hour ambulatory readings, without an increase in antihypertensive medications. The findings could strengthen the case for the procedure and support future adoption, though the announcement does not quantify potential sales impact. Article
• Neutral Sentiment: Medtronic and the Michael J. Fox Foundation launched an educational initiative to help people with Parkinson’s and caregivers understand deep brain stimulation (DBS). It may raise awareness of an established treatment, but no new product, clinical result, or revenue outlook was announced. Article
• Neutral Sentiment: The company said it will release fiscal Q2 2027 results on November 24. This is a scheduling announcement, with no new financial guidance or operating results. Article
• Negative Sentiment: A report said ETFs were net sellers of MDT, with $110.6 million in outflows on Friday. This is a short-term flow signal and may not indicate a lasting change in investor views. Article
• Negative Sentiment: An analyst roundup cited a consensus price target of $102.88, below the $105.02 reference price in the supplied market data, suggesting limited upside at that level. Article

Medtronic Company Profile

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.